交易 Bristol Myers BMY

BristolMyers實時圖表

金融工具基礎知識

Weekly Search
Weekly
Daily
日期 關閉 更改 更改(%): 開倉

BristolMyers 新聞

許景桓 2026 Jun 13, 00:00

聯準會新時代:鮑爾繼任者沃許在通膨與市場擔憂下釋放謹慎信號

陳昊然 2026 Jun 13, 00:00

儲存晶片板塊反彈:AI 是否能延續週期?

許景桓 2026 Jun 13, 00:00

新任聯準會主席沃許:重塑溝通策略,引導市場預期

陳昊然 2026 Jun 13, 00:00

高盛預測2027年布蘭特原油價格降至每桶80美元,供應與需求結構性變化是主因

林芷柔 2026 Jun 13, 00:00

美股交易邏輯瓦解,波動加劇引發市場憂慮

黃達傑 2025 Oct 09, 16:00

臺灣值得關注的加密貨幣:比特幣(BTC)、以太坊(ETH)、索拉納(Solana,SOL)、零幣(Zcash,ZEC)

黃達傑 2025 Sep 29, 16:00

NIO 股票預測:NIO 今天下跌 5%,未來會怎樣?

黃達傑 2025 Sep 27, 16:00

比特幣價格預測:如何在台灣購買比特幣?

黃達傑 2025 Sep 23, 16:00

Fintech 股票值得關注:Nu Holdings(NU)股票、SOFI 股票

黃達傑 2025 Sep 21, 16:00

QBTS 股票今天上漲 11%:D-Wave Quantum Inc. 發生了什麼事?

最新新聞

顯示更多
許景桓 2026 Jun 13, 00:00

卡達能源外交的微妙平衡:地區衝突下的抉擇與風險

張瑋庭 2026 Jun 13, 00:00

黎巴嫩地緣政治角力:伊朗勢力、美國斡旋與主權的艱難求索

張瑋庭 2026 Jun 13, 00:00

全球市場回顧與展望:重點事件與金融市場深度解析

盧昕穎 2026 Jun 13, 00:00

日本央行決策會議受關注:行長健康狀況、升息預期下的溝通挑戰

張瑋庭 2026 Jun 13, 00:00

美伊終戰協議懸而未決:極限施壓下的地緣政治角力

林芷柔 2026 Jun 13, 00:00

美軍奪島伊朗石油樞紐?哈爾克島戰略解析與風險評估

張瑋庭 2026 Jun 13, 00:00

北約安全態勢與美軍部署調整:美歐風險評估分歧加劇

陳昊然 2026 Jun 13, 00:00

霍爾木茲海峽航運格局劇變:非伊朗原油量增,市場波動趨緩

聯絡方式

點差

0.34

點差(%)

0.6210 %

槓桿

1:10

隔夜利息(買入)

-0.0597 %

隔夜利息(賣出)

-0.0292 %

貨幣

USD

交易時間

市場開放

星期三

13:31 - 19:59

星期一

13:31-19:59

星期二

13:31-19:59

星期四

13:31-19:59

星期五

13:31-19:59

分析與統計

開倉

---

上一次平倉

---

52 週高點/低點

--- – ---

市值

113396219904

流通股份

2042071247

收益日期(下一個)

2001-08-07

現金殖利率 

2026-08-03

除息日

2026-07-02

遠期年股息率

2.52

遠期年現金殖利率

0.0461

每股盈餘

3.63

了解有關此金融工具的詳細資訊

Bristol Myers Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for a reduction in risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane for the treatment of breast cancer. Further, it provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; and NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. Bristol-Myers Squibb Company has a strategic collaboration with Arcus Biosciences, Inc. to develop a novel treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

相關工具

資產
出售
購買
更改(%):
查看所有金融工具

最新教育文章

顯示更多
林芷柔 2025 Oct 29, 16:00

進階交易策略:多頭部位 vs. 空頭部位,哪個更好?

黃達傑 2025 Oct 13, 16:00

Palantir(PLTR)股價預測:PLTR暴跌5%,Palantir股價會再度飆升嗎?

黃達傑 2025 Oct 13, 16:00

Nvidia(NVDA)股價今日走高:2026年目標價是多少?

Trustpilot